Small molecules targeting BRCA1-deficient cancer cells
Abstract
BRCA1 mutation-carriers frequently develop triple-negative breast cancers that are resistant to cancer therapies. We used our established luciferase-expressing BRCA1-deficient human mammary epithelial-derived cell line series with stable shRNA-mediated BRCA1-knockdown, H-RasG12V-mediated transformation, and TP53-deficiency (PMID: 20038817) to perform a high-throughput-screen using the National Cancer Institute (NCI) chemical library Diversity Set II of 1,440 small molecules and noninvasive bioluminescence imaging. We selected five (NSC667251, NSC636948, NSC21683, NSC281383, and NSC136513) compounds that reproducibly induced cell death in engineered BRCA1-knockdown cells and in BRCA1-deficient human cancer cell lines. In p53-mutant MDA-MB-231 and SKBr3 lines, the compounds induced apoptosis and PARP cleavage by 12 hours. Sub-G1 flow cytometric analysis demonstrated maximal apoptosis induction by 48 hours of drug exposure. p53 protein stabilization and phosphorylation were observed with the selected compounds in BRCA1-deficient wild-type TP53-expressing cells. Drug-treated BRCA1-knockdown MCF10A cells and BRCA1-mutant HCC-1937 breast cancer cells showed gamma-H2AX foci and phospho-H2AX by immunoblotting indicating genotoxicity and DNA damage as contributing factors for apoptosis. NSC636948 was previously characterized as an inhibitory ligand of peroxisome proliferator-activated beta, delta; (PPAR beta, delta) and both NSC636948 and NSC667251 act as inverse agonists of PPAR beta, delta. Kaplan Meier survival analysis of a combined breast cancer cohort (n = 1,959) derived from the METABRIC, demonstrated that patients with high PPARD expression exhibited significantly worse overall survival compared with those with low PPARD expression (log-rank p = 0.008). The selected compounds provide candidate therapeutic leads as well as insights into molecular targets for further evaluation in BRCA1-deficient tumor models and for assessment in combination therapy strategies.
Related
- FANCM restrains structural genome evolution and defines a synthetic lethal dependency in BRCA1-deficient breast cancer
- Targeting cancer stem cells: advances in small molecules, biologics, and immunotherapies
- A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins
- Small molecules targeting ARF1 interaction with C9orf72:SMCR8:WDR41 complexes suppress its overactivation implicated in ALS/FTD
- Case Report: Coexpression of somatic EGFR, BRCA1, and BRCA2 mutations in metastatic non-small cell lung cancer
BibTeX
@misc{navaraj2026small,
title = {{Small molecules targeting BRCA1-deficient cancer cells}},
author = {Arunasalam Navaraj and Shengliang Zhang and Chris Egg-Krings and Kevin Si and Jean-Nicolas Gallant and Jay Gopal and Sriya S.P. Datla and David T. Dicker and Dinara Ryspayeva and Wafik S. El-Deiry},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.21.760761},
url = {https://www.biorxiv.org/content/10.64898/2026.10.21.760761v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Small molecules targeting BRCA1-deficient cancer cells
AU - Arunasalam Navaraj
AU - Shengliang Zhang
AU - Chris Egg-Krings
AU - Kevin Si
AU - Jean-Nicolas Gallant
AU - Jay Gopal
AU - Sriya S.P. Datla
AU - David T. Dicker
AU - Dinara Ryspayeva
AU - Wafik S. El-Deiry
PY - 2026
DA - 2026/10/21
PB - bioRxiv
DO - 10.64898/2026.10.21.760761
UR - https://www.biorxiv.org/content/10.64898/2026.10.21.760761v1
AB - BRCA1 mutation-carriers frequently develop triple-negative breast cancers that are resistant to cancer therapies. We used our established luciferase-expressing BRCA1-deficient human mammary epithelial-derived cell line series with stable shRNA-mediated BRCA1-knockdown, H-RasG12V-mediated transformation, and TP53-deficiency (PMID: 20038817) to perform a high-throughput-screen using the National Cancer Institute (NCI) chemical library Diversity Set II of 1,440 small molecules and noninvasive bioluminescence imaging. We selected five (NSC667251, NSC636948, NSC21683, NSC281383, and NSC136513) compounds that reproducibly induced cell death in engineered BRCA1-knockdown cells and in BRCA1-deficient human cancer cell lines. In p53-mutant MDA-MB-231 and SKBr3 lines, the compounds induced apoptosis and PARP cleavage by 12 hours. Sub-G1 flow cytometric analysis demonstrated maximal apoptosis induction by 48 hours of drug exposure. p53 protein stabilization and phosphorylation were observed with the selected compounds in BRCA1-deficient wild-type TP53-expressing cells. Drug-treated BRCA1-knockdown MCF10A cells and BRCA1-mutant HCC-1937 breast cancer cells showed gamma-H2AX foci and phospho-H2AX by immunoblotting indicating genotoxicity and DNA damage as contributing factors for apoptosis. NSC636948 was previously characterized as an inhibitory ligand of peroxisome proliferator-activated beta, delta; (PPAR beta, delta) and both NSC636948 and NSC667251 act as inverse agonists of PPAR beta, delta. Kaplan Meier survival analysis of a combined breast cancer cohort (n = 1,959) derived from the METABRIC, demonstrated that patients with high PPARD expression exhibited significantly worse overall survival compared with those with low PPARD expression (log-rank p = 0.008). The selected compounds provide candidate therapeutic leads as well as insights into molecular targets for further evaluation in BRCA1-deficient tumor models and for assessment in combination therapy strategies.
SN - 2692-8205
ER -